CD8A and neoplasm: Using the Discovery Ultra Autostainer (Ventana Medical Systems, Tucson AZ), the researchers found that the distance between CD3+/CD8+ T cells and cancer cells was shortened under anti-HER2-based neoadjuvant treatment, indicating the strong predictive value of the spatial relationships of specific immune cell subsets and tumor cells (39).